Alterity Therapeutics Limited (FRA:PBN)

Market Cap	52.22M +13.3%
Revenue (ttm)	3.04M +35.3%
Net Income	-6.78M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0050
Previous Close	0.0050
Day's Range	0.0050 - 0.0050
52-Week Range	0.0030 - 0.0100
Beta	n/a
RSI	66.42
Earnings Date	Feb 25, 2026

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 9
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PBN

Financial Performance

In fiscal year 2025, Alterity Therapeutics's revenue was 5.44 million, an increase of 35.32% compared to the previous year's 4.02 million. Losses were -12.15 million, -36.48% less than in 2024.

Financial numbers in AUD